Back to the Top
Dear All,
Anybody knows the CV (coefficient of variability individual) of
efavirenz ?
Atenciosamente,
BERNARDINO SILVA
UNIDADE DE AVALIACAO DE ESTUDOS DE BIODISPONIBILIDADE E
BIOEQUIVALENCIA DE MEDICAMENTOS / UABBE
GERENCIA GERAL DE MEDICAMENTOS - GGMED
AGENCIA NACIONAL DE VIGILANCIA SANITARIA - ANVISA
MINISTERIO DA SAUDE- MS
Back to the Top
The following message was posted to: PharmPK
Dear Bernadino,
This depends on the pharmacokinetic parameter you are referring to
(AUC? Cmin? Clearance? Etc). A lot of work on the population
pharmacokinetics of efavirenz in adults as well as children has been
performed in adutls as well as in children. The interindividual
variability in clearance of efavirenz also depends on the genetic
variations in the CYP2B6 gene, which depends on the population.
Please refer to these article for more info:
ter Heine R, Scherpbier HJ, Crommentuyn KC, Bekker V, Beijnen JH,
Kuijpers TW, Huitema AD. A pharmacokinetic and pharmacogenetic study of
efavirenz in children: dosing guidelines can result in subtherapeutic
concentrations - Antivir Ther (IN PRESS)
Kappelhoff BS, Huitema AD, Yalvac Z, Prins JM, Mulder JW, Meenhorst PL,
Beijnen JH.
Population pharmacokinetics of efavirenz in an unselected cohort of
HIV-1-infected individuals.
Clin Pharmacokinet. 2005;44(8):849-61.
Kappelhoff BS, van Leth F, MacGregor TR, Lange J, Beijnen JH, Huitema
AD; 2NN Study Group.
Nevirapine and efavirenz pharmacokinetics and covariate analysis in the
2NN study.
Antivir Ther. 2005;10(1):145-55.
Sincerely,
Rob ter Heine
Back to the Top
The following message was posted to: PharmPK
I am referring to AUC and Cmax.
Want to post a follow-up message on this topic?
If this link does not work with your browser send a follow-up message to PharmPK@boomer.org with "Efavirenz CV" as the subject | Support PharmPK by using the |
Copyright 1995-2011 David W. A. Bourne (david@boomer.org)